A Study of GZR18 Injection in Chinese Obese/Overweight Patients

Summary

The study was a multicenter, randomized, double-blind, placebo-controlled phase Ib/IIa clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of GZR18 injection in Chinese adult obese/overweight patients. This study is divided into Part A and Part B, which are to be conducted simultaneously.

Timeline

Start

2022-07-14

Primary completion

2023-10-22

Completion

2023-10-22

Publications

• Ji L, Gao L, Dong R, Yuan M, Zhao D, Pang S, Zhao J, Zhao L, Chen W. GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b/2a trial. Cell Rep Med. 2026 Apr 21;7(4):102743. doi: 10.1016/j.xcrm.2026.102743. Epub 2026 Apr 8.

Drugs

Indications